|
 |
| We are focusing on the development of long-acting biopharmaceuticals and oral oncology drugs with our proprietary platform technologies. |
 LAPSCOVERY Technology (Long-Acting Protein Discovery Technology) |
| Our advanced platform technology extends the half-life of a bio-pharmaceutical and enables high in vivo efficacy and potency
by simple conjugation with a bio-carrier named LAPS Carrier |
| >> more |
|
| ORASCOVERY Technology (Oral Drug Discovery Technology) |
Hanmi has succeeded in developing Pgp Inhibitor, HM30181A, which enables
anticancer drugs to be absorbed orally. Using this molecule, we are developing
oral formulation anticancer drugs such as oral Paclitaxel, oral Irinotecan and
so on. We are also focusing on the development of targeted anticancer drugs
which can modulate signal transduction pathways. |
| >> more |
|
 |
|
|
 |
|
|
|
|
|
|
|
|
